Device Trial Radar · NCT03530306
Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
191
Actual
Start
Mar 20, 2018
Primary completion
Oct 2, 2018
Study completion Jul 18, 2019
Sponsor
- Lead sponsor
- Neuromod Devices Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 21, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a four arm, patient subtyping and parameter optimisation study for a neuromodulation treatment for tinnitus.
Conditions
- Tinnitus
Interventions
PS1-PS4Device
Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
PS6-PS10Device
Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
PS7-PS4Device
Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
PS9-PS6Device
Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tinnitus Handicap Inventory (THI)Time frame: Between-arm and within-arm changes in THI after 6 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. James's Wellness Trust Clinical Research Facility
Dublin, Ireland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.